Molecular Profile Detail

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Molecular Profile Indication/Tumor Type Response Type Relevant Treatment Approaches Therapy Name Approval Status Evidence Type Efficacy Evidence References
KRAS G13D colon cancer no benefit PI3K Inhibitor (Pan) Buparlisib Preclinical Actionable In a preclinical studu, BKM120 alone failed to induce tumor regression in mouse xenograft models of Kras G13D mutant colorectal cancer (PMID: 24576621). 24576621
KRAS G13D colorectal cancer sensitive MEK inhibitor (Pan) MEK1 Inhibitor MEK2 Inhibitor Pimasertib + Sorafenib Preclinical - Cell culture Actionable In a preclinical study, Pimasertib (MSC1936369B) and Nexavar (sorafenib) synergistically inhibited proliferation of colorectal cancer cells harboring KRAS G13D in culture (PMID: 23629727). 23629727
KRAS G13D non-small cell lung carcinoma sensitive AZD4785 AZD4785 Preclinical - Cell line xenograft Actionable In a preclinical study, AZD4785 inhibited Kras expression, resulted in growth inhibition in 3-D cultures of non-small cell lung carcinoma cells harboring KRAS G13D, and anti-tumor activity in cell line xenograft models (PMID: 28615361). 28615361
KRAS G13D colorectal cancer sensitive Oxaliplatin Preclinical Actionable In a preclinical study, sensitivity to Eloxatin (oxaliplatin) was increased in colon tumor cell lines carrying KRAS G13D (PMID: 23209813). 23209813
KRAS G13D colorectal cancer resistant Regorafenib Preclinical Actionable In a preclinical study, human colorectal cancer cells harboring KRAS G13D were resistant to Stivarga (regorafenib) in culture (PMID: 25838391). 25838391
KRAS G13D colorectal cancer sensitive MEK inhibitor (Pan) MEK1 Inhibitor MEK2 Inhibitor Pimasertib + Regorafenib Preclinical - Cell culture Actionable In a preclinical study, Pimasertib (MSC1936369B) and Stivarga (regorafenib) synergistically inhibited proliferation of colorectal cancer cells harboring KRAS G13D in culture (PMID: 23629727). 23629727
KRAS G13D colorectal cancer resistant Sunitinib Preclinical Actionable In a preclinical study, a colorectal cancer cell line harboring the KRAS G13D mutation showed resistance to Sutent (sunitinib) treatment (PMID: 23455880). 23455880
KRAS G13D colorectal cancer decreased response MEK inhibitor (Pan) MEK1 Inhibitor MEK2 Inhibitor Pimasertib Preclinical - Cell culture Actionable In a preclinical study, colorectal cancer cells harboring KRAS G13D demonstrated decreased response to Pimasertib (MSC1936369B) in culture (PMID: 23629727). 23629727
KRAS G13D colorectal cancer resistant Cetuximab Clinical Study Actionable In a clinical study, KRAS mutations in codon 12 or 13 were associated with resistance to Erbitux (cetuximab) in colorectal cancer patients (PMID: 18202412). 18202412
KRAS G13D colorectal adenocarcinoma sensitive MEK inhibitor (Pan) MEK1 Inhibitor MEK2 Inhibitor RO5126766 Preclinical - Cell culture Actionable In a preclinical study, RO5126766 inhibited proliferation of colorectal adenocarcinoma cells harboring KRAS G13D in culture (PMID: 26438159). 26438159
KRAS G13D Advanced Solid Tumor predicted - resistant RMC-4550 Preclinical - Cell line xenograft Actionable In a preclinical study, RMC-4550 did not inhibit growth of cancer cell lines harboring KRAS G13D in 3D culture, and did not inhibit tumor growth in cell line xenograft models (PMID: 30104724). 30104724
KRAS G13D colorectal cancer sensitive LY3009120 Preclinical Actionable In a preclinical study, LY3009120 inhibited growth of, and blocked MAPK signaling in human colorectal cancer cells harboring KRAS G13D in culture (PMID: 26343583). 26343583
KRAS G13D breast cancer sensitive RAS Inhibitor (Pan) 3144 Preclinical - Cell line xenograft Actionable In a preclinical study, 3144 inhibited growth of a breast cancer cell line harboring KRAS G13D in culture and reduced tumor growth in xenograft models (PMID: 28235199). 28235199
KRAS G13D colorectal cancer predicted - resistant RMC-4550 Preclinical - Cell line xenograft Actionable In a preclinical study, RMC-4550 did not inhibit growth of colorectal cancer cell lines harboring KRAS G13D in 3D culture, and did not inhibit tumor growth in cell line xenograft models (PMID: 30104724). 30104724
KRAS G13D Advanced Solid Tumor sensitive MEK inhibitor (Pan) GDC-0623 Preclinical - Cell line xenograft Actionable In a preclinical study, GDC-0623 demonstrated efficacy against both KRAS-mutant and BRAF-mutant cancer models in cell based assays and cell line xenografts (PMID: 23934108). 23934108
KRAS G13D colorectal cancer sensitive Regorafenib + Cetuximab Preclinical Actionable In a preclinical study, the combination of Erbitux (cetuximab) and Stivarga (regorafenib) inhibited growth, reduced Akt and Mapk phosphorylation, and induced apoptosis in human colorectal cancer cell lines harboring KRAS G13D in culture (PMID: 25838391). 25838391
KRAS G13D colorectal cancer sensitive MEK inhibitor (Pan) MEK1 Inhibitor MEK2 Inhibitor Cobimetinib Preclinical - Cell line xenograft Actionable In a preclinical study, Cobimetinib (GDC-0973) inhibited tumor growth in xenograft models of human colorectal cancer cell lines harboring KRAS G13D (PMID: 23934108). 23934108
KRAS G13D colorectal cancer sensitive PI3K Inhibitor (Pan) rigosertib Preclinical - Cell line xenograft Actionable In a preclinical study, Estybon (rigosertib) inhibited Mek/Erk signaling and tumor growth in cell line xenograft models of colorectal cancer harboring KRAS G13D (PMID: 27104980). 27104980
KRAS G13D lung cancer predicted - resistant RMC-4550 Preclinical - Cell culture Actionable In a preclinical study, RMC-4550 did not inhibit growth of colorectal cancer cells harboring KRAS G13D in 3D culture (PMID: 30104724). 30104724
KRAS G13D colon cancer sensitive MEK inhibitor (Pan) MEK1 Inhibitor MEK2 Inhibitor APS-2-79 + Trametinib Preclinical - Cell culture Actionable In a preclinical study, the combination of APS-2-49 and Mekinist (trametinib) worked synergistically to decrease viability of a colon cancer cell line harboring KRAS G13D in culture (PMID: 27556948). 27556948
KRAS G13D colorectal cancer sensitive MEK inhibitor (Pan) MEK1 Inhibitor MEK2 Inhibitor Palbociclib + Trametinib Preclinical - Pdx & cell culture Actionable In a preclinical study, Mekinist (trametinib) and Ibrance (palbociclib) synergistically inhibited growth of colorectal cancer cells harboring KRAS G13D in culture and resulted in partial tumor regression in patient-derived xenograft models (PMID: 26369631). 26369631
KRAS G13D colorectal adenocarcinoma sensitive MEK inhibitor (Pan) MEK1 Inhibitor MEK2 Inhibitor RO4987655 Preclinical - Cell culture Actionable In a preclinical study, RO4987655 inhibited proliferation of colorectal adenocarcinoma cells harboring KRAS G13D in culture (PMID: 26438159). 26438159
KRAS G13D colorectal adenocarcinoma predicted - sensitive MEK inhibitor (Pan) MEK1 Inhibitor MEK2 Inhibitor Selumetinib Preclinical - Cell culture Actionable In a preclinical study, Selumetinib (AZD-6244) inhibited proliferation of colorectal adenocarcinoma cells harboring KRAS G13D in culture (PMID: 26438159). 26438159
KRAS G13D colon cancer sensitive Luminespib Preclinical - Cell line xenograft Actionable In a preclinical study, a colon cancer cell line harboring KRAS G13D demonstrated increased sensitivity to Luminespib (AUY922) compared to cell lines with wild-type KRAS, resulting in decreased viability and increased apoptosis in culture and reduced tumor growth in xenograft models (PMID: 26832792). 26832792
KRAS G13D colorectal cancer sensitive MEK inhibitor (Pan) MEK1 Inhibitor MEK2 Inhibitor Everolimus + Pimasertib Preclinical - Cell culture Actionable In a preclinical study, Pimasertib (MSC1936369B) and Afinitor (everolimus) synergistically inhibited proliferation of colorectal cancer cells harboring KRAS G13D in culture (PMID: 23629727). 23629727
KRAS G13D colorectal cancer decreased response Neratinib Preclinical Actionable In a preclinical study, colorectal cancer cells harboring KRAS G13D were less sensitive to Nerlynx (neratinib) induced growth inhibition in culture (PMID: 26243863). 26243863
KRAS G13D colorectal cancer sensitive RAF709 Preclinical - Cell culture Actionable In a preclinical study, RAF709 inhibited Erk signaling and proliferation of colorectal cancer cells harboring KRAS G13D in culture (PMID: 29343524). 29343524
Clinical Trial Phase Therapies Title Recruitment Status